When was Dermala founded?

Dermala was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is Dermala located?

Dermala is headquartered in San Diego, United States.

How many employees does Dermala have?

As of Aug 31, 2026, the latest employee count at Dermala is 9.

Is Dermala a funded company?

Dermala is a funded company, having raised a total of $7.73M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 16, 2018.

When was the latest funding round of Dermala?

Dermala's latest funding was a $***** Series A round on Oct 12, 2020, with participation from 4 investors.

Where does Dermala rank among its competitors?

Dermala ranks 58th amongst 254 active competitors, of which 59 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Collplant, which secured $4M in Feb, 2026.

Who are the top competitors of Dermala?

Dermala's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Among them, Collplant secured the most recent funding round in February, 2026.

Dermala - 2026 Company Profile, Funding & Competitors

Dermala is a series A company based in San Diego (United States), founded in 2014. It operates as a Developer of therapeutics to treat and prevent diseases associated with the skin microbiome dysbiosis. Dermala has raised $7.73M in funding from Johnson & Johnson Innovation and True Wealth Ventures. The company has 254 active competitors, including 59 funded and 75 that have exited. Its top competitors include companies like Revance Therapeutics, Lineage Cell Therapeutics and Evolus.

Company Details

Dermala is a spinout from the University of California San Diego and JLABS incubator company. They are utilizing the human skin microbiome to develop treatments for skin diseases associated with the skin microbiome dysbiosis. In addition, Dermala is incorporating microbiome sequencing into the treatment decision-making process.

Website: www.dermala.com/
Social

Key Metrics

Founded Year

2014

Location

San Diego, United States

Stage

Series A

Total Funding

$7.73M in 2 rounds

Latest Funding Round

Series A, Oct 12, 2020, $*****

Investors

Johnson & Johnson Innovation & 3 more

Ranked

58^th among 254 active competitors

Employee Count

9 as on Aug 31, 2026

Similar Companies

Revance Therapeutics & 330 more

View Dermala's full profile

Dermala has raised a total funding of $7.73M over 2 rounds. Its first funding round was on Apr 16, 2018. Its latest funding round was a Series A round on Oct 12, 2020 for $*****. 4 investors participated in its latest round. Dermala has 4 institutional investors.

Here is the list of recent funding rounds of Dermala:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 12, 2020	3434277	Series A	9875139	2191592	5963403	7880107
Apr 16, 2018	5653889	Seed	8273722	8557987	8103684	1729867

Access funding benchmarks and valuations. Sign up today!

View details of Dermala's funding rounds and investors

Dermala's employee count trend

Dermala has 9 employees as of Aug 26. Here is Dermala's employee count trend over the years:

Uncover Dermala's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dermala include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Here is the list of Top 10 competitors of Dermala, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	66/100
3rd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
4th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
5th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	61/100
6th	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, HarbourVest Partners & 2 others	60/100
7th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	60/100
8th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
9th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
10th	Synlogic Therapeutics 2013, Cambridge (United States), Public	Developer of drugs using engineered microbes	$34.4M	Gates, Atlas Venture & 15 others	59/100
58th	Dermala 2014, San Diego (United States), Series A	Developer of therapeutics to treat and prevent diseases associated with the skin microbiome dysbiosis	$7.73M	Seventure Partners, Johnson & Johnson Innovation ... & 2 others	37/100